<u>REMARKS</u>

Upon entry of the above amendment, claims 1, 4-9, 11 and 15-21 will be pending in the present application. Applicants canceled claims 2, 3, 10 and 12-14. Applicants withdrew claims 9 and 16-21 as a result of an election. Applicants amended claims 1, 4-8 and 11. No new matter has been added.

The specification at page 8, line 22 to page 9, line 9 and page 14, lines 2-3 provides support for the amendments to claims 1, 4, 6 and 11. Applicants amended claims 5, 7 and 8 to clarify the invention.

Rejection of Claims 1-8, 11-12 and 14 under 35 U.S.C. § 112, first paragraph

Claims 1-8, 11-12 and 14 stand rejected under 35 U.S.C. § 112, first paragraph because, according to the Examiner, "the specification, while being enabling for L as pyrazole and W as phenyl-oxazole, does not reasonably provide enablement for the remaining scope of rings."

Solely for the purpose of expediting prosecution, claim 1 and dependent claims 4-8 and 11 have been amended to define L as pyrazole and W as phenyl-oxazole. Applicants cancled claims 2, 3, 12 and 14.

Applicants respectfully request withdrawal of the rejection of claims 1, 4-8 and 11 under 35 U.S.C. § 112, first paragraph.

Rejection of Claim 1 under 35 U.S.C. § 102(b)

Claim 1 stands rejected under 35 U.S.C. § 102(b) as being anticipated by Vidyasagar et al. (J. Indian Chem. Soc. 1991; 68(10):576-578). Applicants respectfully disagree.

Claim 1 is directed to compounds wherein W is phenyl substituted oxazole and L is pyrazole.

In contrast, Vidyasagar et al. describe compounds wherein W is either substituted oxadiazole or substituted triazole and L is methyl substituted isoxazole. Vidyasagar et al. neither disclose nor suggest compounds wherein W is phenyl substituted oxazole and L is pyrazole. Vidyasagar et al. fails to anticipte claim 1 as amended.

Applicants respectfully request reconsideration and withdrawal of the rejection of claim 1 under 35 U.S.C. § 102(b).

Conclusion

Applicants have addressed each and every issue set forth by the Examiner. Applicants respectfully submit that the present application is in good condition for allowance.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617) 871-4125. If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 50-4409 for any additional fees under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly extension of time fees.

Respectfully submitted,

Novartis Institute for Biomedical Research NIBR Patents 400 Technology Square Cambridge, MA 02139 (617) 871-4125

Date: November 13, 2008

Mark W. Milstead Attorney for Applicant Reg. No. 45,825